Tremfya and Stelara are both Johnson & Johnson biologics for moderate-to-severe Crohn's disease, and they present a rare scenario where a manufacturer's newer drug is being compared head-to-head with its predecessor. Stelara has been the workhorse IL-12/23 biologic in IBD since its Crohn's approval in 2016. Tremfya is a newer p19-selective IL-23 biologic that J&J brought to IBD markets starting in 2024. The GALAXI 2 and GALAXI 3 trials directly compared these two drugs in Crohn's, and the results favor Tremfya on endoscopic endpoints. This guide walks through what Crohn's patients need to know when weighing the tremfya vs stelara crohn's decision.
IL-23 p19 vs IL-12/23 p40
Stelara (ustekinumab) binds the p40 subunit shared by interleukin-12 and interleukin-23, blocking both cytokines. Tremfya (guselkumab) binds the p19 subunit of IL-23 alone, leaving IL-12 signaling intact. The guselkumab vs ustekinumab distinction matters because IL-23 is increasingly recognized as the dominant driver of pathogenic T-cell subsets in Crohn's, while IL-12 plays roles in normal immune surveillance that may not need blocking. By sparing IL-12 and narrowing the target to IL-23, p19-selective biologics theoretically deliver cleaner efficacy with a potentially better safety margin. GALAXI was designed to test whether this translates into real clinical differences in Crohn's.
The GALAXI Trial Program
GALAXI 1 was a phase 2 trial establishing Tremfya's efficacy in Crohn's. GALAXI 2 and GALAXI 3 were the pivotal phase 3 head-to-head trials comparing guselkumab with ustekinumab in moderate-to-severe Crohn's. Both trials randomized biologic-naive and biologic-experienced patients to guselkumab (at two dose arms) or ustekinumab, with placebo arms for initial comparison. At week 12, all guselkumab arms met primary endpoints for clinical response. By week 48 to 52, guselkumab demonstrated superiority over ustekinumab on endoscopic endpoints, with endoscopic response rates of 44% to 46% for guselkumab compared with about 30% for ustekinumab. Clinical remission rates favored guselkumab across both GALAXI 2 and 3. The combined data package led to Tremfya's FDA approval for Crohn's in 2024.
Who Benefits Most
GALAXI included both biologic-naive and biologic-experienced Crohn's patients, which means the data applies broadly. Patients who have already failed an anti-TNF typically benefit from a mechanism change, and the GALAXI data supports guselkumab as a strong choice in this population. Biologic-naive patients also showed superior endoscopic outcomes on guselkumab. For patients currently doing well on Stelara, switching to Tremfya is not generally recommended, because responders should stay on working therapy. For patients on Stelara with partial response, rising inflammatory markers, or endoscopic activity, a switch to Tremfya is a reasonable consideration given the GALAXI endoscopic outcomes.
Safety Profiles
Both drugs have favorable safety profiles relative to anti-TNFs, and the GALAXI trials did not identify new safety signals for either. Rates of serious adverse events, serious infections, and discontinuations were similar between guselkumab and ustekinumab arms. Both carry boxed warnings related to serious infections, both require TB and hepatitis B screening before starting, and both are typically used as monotherapy. Long-term safety data for guselkumab is shorter than for ustekinumab simply because it has been on the market for fewer years, though extensive psoriasis and psoriatic arthritis experience supports its long-term profile. For tremfya vs stelara crohn's effectiveness and tolerability, the GALAXI data suggests similar safety with a meaningful efficacy advantage for guselkumab.
Dosing and Administration
Tremfya for Crohn's uniquely offers dual induction options. The IV induction is 200 mg at weeks 0, 4, and 8. A separate subcutaneous induction pathway uses 400 mg at weeks 0, 4, and 8, allowing patients to avoid infusion centers entirely. Maintenance is 100 mg SC every 8 weeks or 200 mg SC every 4 weeks, giving patients and clinicians flexibility based on response. Stelara uses a single weight-based IV induction dose, then 90 mg SC every 8 weeks. For patients who want to avoid IV induction, Tremfya's SC induction is a meaningful practical advantage. For patients who prefer the simplest long-term maintenance, Stelara's single every-8-week dose is slightly more streamlined than Tremfya's tiered options.
Cost and Access
Both drugs are branded biologics. Stelara biosimilars became available in the US starting in 2025, with several interchangeable ustekinumab biosimilars reaching market, which has lowered acquisition costs and shifted formulary preferences. Tremfya has no biosimilar and relies on branded pricing. For Crohn's patients where insurance strongly prefers a ustekinumab biosimilar, Stelara may be the easier drug to access at low out-of-pocket cost. For patients whose plans cover branded biologics without major cost differences, Tremfya's GALAXI-demonstrated endoscopic superiority often justifies the choice. Manufacturer copay assistance programs for Tremfya can help bridge the cost gap for commercially insured patients.
Choosing With Your GI
For a Crohn's patient choosing between Tremfya and Stelara, GALAXI 2 and 3 provide direct head-to-head evidence favoring guselkumab on endoscopic outcomes and most clinical endpoints. For patients prioritizing endoscopic healing or those who have failed an anti-TNF, Tremfya often becomes the preferred option. For patients already doing well on Stelara or those where a ustekinumab biosimilar is the cost-effective path, Stelara remains a reasonable choice. Ask your GI how response will be measured after induction, what to do if symptoms persist, and whether cost or insurance access favors one option. A log of stool frequency, urgency, abdominal pain, and any new extraintestinal symptoms between visits helps your care team recognize partial response or early loss of response before a full flare returns.
This article is for educational purposes and is not medical advice. It is researched against current AGA clinical guidelines and peer-reviewed sources. Always discuss treatment decisions with your care team.